Improved quality of life and prolonged survival with add-on homeopathic treatment in patients with non-small cell lung cancer: a prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter study.
Support Care CancerSep 10, 2026 (epub)
Michael Frass, Peter Lechleitner, Christa Gründling et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, randomized, placebo-controlled trial evaluated the effects of add-on homeopathic treatment on quality of life (QoL) and survival in 98 patients with stage IV non-small cell lung cancer (NSCLC). The homeopathy group showed significantly improved QoL and a median survival of 435 days compared to 257 days in the placebo group (p=0.010).
Key findings
- Global health status QoL was significantly higher in the homeopathy group than in the placebo group after 9 and 18 weeks (p<0.001).
- Median survival was 435 days for the homeopathy group versus 257 days for the placebo group (p=0.010).
- Two-year survival rates were 45.1% for homeopathy, 23.4% for placebo, and 13.5% for control (homeopathy vs. placebo p=0.020).
Why it matters
The findings suggest that adjunctive homeopathy may enhance quality of life and prolong survival in patients with advanced NSCLC, potentially offering a complementary approach to conventional cancer therapies.